Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The treatment armamentarium for metastatic castration-resistant prostate cancer (mCRPC) has increased significantly over the past several years. Approved drugs associated with improved survival include androgen pathway-targeted agents (abiraterone acetate and enzalutamide), chemotherapeutics (docetaxel and cabazitaxel), an autologous vaccine (sipuleucel-T) and a radiopharmaceutical (radium-223). Abiraterone acetate, a prodrug of abiraterone, inhibits the CYP17A enzyme, a critical enzyme in androgen biosynthesis. Abiraterone has regulatory approval in mCRPC in both chemotherapy-naïve patients and in the post-docetaxel setting based on results from two randomized phase III studies. In the COU-AA-302 trial, abiraterone demonstrated significant improvement in the coprimary endpoints of radiographic progression-free survival and overall survival, as well as in a number of secondary endpoints including time until initiation of chemotherapy, time until opiate use for cancer-related pain, prostate-specific antigen progression-free survival and decline in performance status. Abiraterone is well-tolerated, although adverse events associated with this agent include abnormalities in liver function testing and mineralocorticoid-associated adverse events. This review evaluates the use of abiraterone in mCRPC prior to the use of chemotherapy.

Original languageEnglish (US)
Pages (from-to)194-202
Number of pages9
JournalTherapeutic Advances in Urology
Volume7
Issue number4
DOIs
StatePublished - Aug 21 2015

Fingerprint

Castration
docetaxel
Prostatic Neoplasms
Drug Therapy
Androgens
Disease-Free Survival
Opiate Alkaloids
Radium
Mineralocorticoids
Survival
Radiopharmaceuticals
Prodrugs
Enzymes
Prostate-Specific Antigen
Vaccines
abiraterone
Liver
Pharmaceutical Preparations
Abiraterone Acetate

Keywords

  • abiraterone
  • castration-resistant
  • chemotherapy-naïve
  • prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this

Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy. / Gartrell, Benjamin A.; Saad, Fred.

In: Therapeutic Advances in Urology, Vol. 7, No. 4, 21.08.2015, p. 194-202.

Research output: Contribution to journalArticle

@article{c6527c0b9a264525bb6625c0fca4b739,
title = "Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy",
abstract = "The treatment armamentarium for metastatic castration-resistant prostate cancer (mCRPC) has increased significantly over the past several years. Approved drugs associated with improved survival include androgen pathway-targeted agents (abiraterone acetate and enzalutamide), chemotherapeutics (docetaxel and cabazitaxel), an autologous vaccine (sipuleucel-T) and a radiopharmaceutical (radium-223). Abiraterone acetate, a prodrug of abiraterone, inhibits the CYP17A enzyme, a critical enzyme in androgen biosynthesis. Abiraterone has regulatory approval in mCRPC in both chemotherapy-na{\"i}ve patients and in the post-docetaxel setting based on results from two randomized phase III studies. In the COU-AA-302 trial, abiraterone demonstrated significant improvement in the coprimary endpoints of radiographic progression-free survival and overall survival, as well as in a number of secondary endpoints including time until initiation of chemotherapy, time until opiate use for cancer-related pain, prostate-specific antigen progression-free survival and decline in performance status. Abiraterone is well-tolerated, although adverse events associated with this agent include abnormalities in liver function testing and mineralocorticoid-associated adverse events. This review evaluates the use of abiraterone in mCRPC prior to the use of chemotherapy.",
keywords = "abiraterone, castration-resistant, chemotherapy-na{\"i}ve, prostate cancer",
author = "Gartrell, {Benjamin A.} and Fred Saad",
year = "2015",
month = "8",
day = "21",
doi = "10.1177/1756287215592288",
language = "English (US)",
volume = "7",
pages = "194--202",
journal = "Therapeutic Advances in Urology",
issn = "1756-2872",
publisher = "SAGE Publications Inc.",
number = "4",

}

TY - JOUR

T1 - Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy

AU - Gartrell, Benjamin A.

AU - Saad, Fred

PY - 2015/8/21

Y1 - 2015/8/21

N2 - The treatment armamentarium for metastatic castration-resistant prostate cancer (mCRPC) has increased significantly over the past several years. Approved drugs associated with improved survival include androgen pathway-targeted agents (abiraterone acetate and enzalutamide), chemotherapeutics (docetaxel and cabazitaxel), an autologous vaccine (sipuleucel-T) and a radiopharmaceutical (radium-223). Abiraterone acetate, a prodrug of abiraterone, inhibits the CYP17A enzyme, a critical enzyme in androgen biosynthesis. Abiraterone has regulatory approval in mCRPC in both chemotherapy-naïve patients and in the post-docetaxel setting based on results from two randomized phase III studies. In the COU-AA-302 trial, abiraterone demonstrated significant improvement in the coprimary endpoints of radiographic progression-free survival and overall survival, as well as in a number of secondary endpoints including time until initiation of chemotherapy, time until opiate use for cancer-related pain, prostate-specific antigen progression-free survival and decline in performance status. Abiraterone is well-tolerated, although adverse events associated with this agent include abnormalities in liver function testing and mineralocorticoid-associated adverse events. This review evaluates the use of abiraterone in mCRPC prior to the use of chemotherapy.

AB - The treatment armamentarium for metastatic castration-resistant prostate cancer (mCRPC) has increased significantly over the past several years. Approved drugs associated with improved survival include androgen pathway-targeted agents (abiraterone acetate and enzalutamide), chemotherapeutics (docetaxel and cabazitaxel), an autologous vaccine (sipuleucel-T) and a radiopharmaceutical (radium-223). Abiraterone acetate, a prodrug of abiraterone, inhibits the CYP17A enzyme, a critical enzyme in androgen biosynthesis. Abiraterone has regulatory approval in mCRPC in both chemotherapy-naïve patients and in the post-docetaxel setting based on results from two randomized phase III studies. In the COU-AA-302 trial, abiraterone demonstrated significant improvement in the coprimary endpoints of radiographic progression-free survival and overall survival, as well as in a number of secondary endpoints including time until initiation of chemotherapy, time until opiate use for cancer-related pain, prostate-specific antigen progression-free survival and decline in performance status. Abiraterone is well-tolerated, although adverse events associated with this agent include abnormalities in liver function testing and mineralocorticoid-associated adverse events. This review evaluates the use of abiraterone in mCRPC prior to the use of chemotherapy.

KW - abiraterone

KW - castration-resistant

KW - chemotherapy-naïve

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84937396418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937396418&partnerID=8YFLogxK

U2 - 10.1177/1756287215592288

DO - 10.1177/1756287215592288

M3 - Article

VL - 7

SP - 194

EP - 202

JO - Therapeutic Advances in Urology

JF - Therapeutic Advances in Urology

SN - 1756-2872

IS - 4

ER -